Bayer AG announced a strategic restructuring of its agricultural portfolio to focus on 10 key blockbuster products, aiming to generate 500 million euros in profit from each. ^[1] Bayer is introducing Preceon, a low-height corn system already commercialized in Mexico, Italy, Spain, and the United States, with plans to expand to 26 million acres by 2035. ^[2] In Brazil, Bayer plans to launch Intacta 5+ during the 2027-2028 agricultural cycle, featuring five herbicide tolerances and new insect protection attributes. ^[3] The restructuring involves cutting investments in lower-performing product lines, with the company expecting these measures to contribute an additional 1,000 million euros to its EBITDA before extraordinary items by the end of the decade. ^[4] A research paper titled 'Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium' reports on the short-term impact of combined heart failure therapies on these three clinical parameters. ^[5] The article's data availability statement says all trial funders are committed to sharing access to patient-level data and supporting clinical documents from eligible studies, subject to each funder's criteria and processes. ^[6] The trial funders named in the data availability statement are AstraZeneca, Bayer, Novartis, and Pfizer, each with its own data-sharing criteria and processes. ^[7] The paper's reference list includes the American Heart Association's 2026 Heart Disease and Stroke Statistics and numerous studies on heart failure pharmacotherapy, such as the CHAMP-HF registry and the STRONG-HF trial. ^[8]